Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VEGF Trap in Recurrent or Metastatic Urothelial Carcinoma
NCT00407485Phase 2Completed
- Sponsor
- National Cancer Institute
- Start
- Nov 2006
- Primary completion
- Apr 2010
- Modality
- Engineered Antibody Formats, Fc-Fusion Proteins
- Countries
- 1
01
Overview
A Phase 2 trial of aflibercept in transitional cell carcinoma of the urothelium (TCC), sponsored by National Cancer Institute. Started Nov 2006; status: completed.
02
Drugs
aflibercept
03
Conditions
transitional cell carcinoma of the urothelium (TCC)
Beyond the preview
Go deeper on NCT00407485.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00407485.